---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-258629"
form_type: "8-K"
ticker: "SVRA"
cik: "0001160308"
company_name: "Savara Inc"
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:14:42.393767+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share

## Summary
- 23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.
- Underwriters granted 30-day option to purchase up to an additional 4.6M shares.
- Proceeds to fund clinical development and regulatory approval of MOLBREEVI, plus commercialization and launch prep in US and EU.
- Offering expected to close October 31, 2025, subject to customary conditions.
- Jefferies, Piper Sandler, and Guggenheim Securities are joint book-running managers.

## SEC filing metadata
- accession: 0001193125-25-258629
- form_type: 8-K
- ticker: SVRA
- cik: 0001160308
- company_name: Savara Inc
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1160308/000119312525258629/0001193125-25-258629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1160308/000119312525258629/d62228d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-258629
- JSON: https://secwatch.observer/filing/0001193125-25-258629.json
- Plain text: https://secwatch.observer/filing/0001193125-25-258629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.